Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus GLEOSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus GLEOSTINE.
EVOMELA vs GLEOSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Category C
Category C
Alkylating Agent
Alkylating Agent